投稿一覧に戻る
Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ(株)【4598】の掲示板 2024/04/27〜2024/05/07
-
966
>>965
Idasanutlinのcytarabineとの併用は、
overall remission rate (CR+CRi+CRp)を改善するも、OSは改善しなかった。
やっぱりOS大事だね。
Blood Adv. 2022 Jul 26; 6(14): 4147–4156.
(Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327534/
far*****
>>964
GilteritinibのP3試験（r/r FLT3-Mutated AML）
（NCT02421939、N Engl J Med. 2019;381:1728-1740.）
計371症例（Primary end point：OS、CR with full or partial hematologic recovery）
Gilteritinib (n = 247) vs. Salvage chemotherapy (n = 124)
Median OS: 9.3 (95% CI 7.7-10.7) vs. 5.6 (95% CI 4.7-7.3)
(Hazard ratio for death=0.64、95% CI 0.49-0.83, P<0.001)
CR with fHazard ratio for death, 0.64 (95% CI, 0.49-0.83, P<0.001)
ull or partial hematologic recovery: 34.0% vs. 15.3%
(risk difference, 18.6 percentage points; 95% CI, 9.8 to 27.4)
CR: 21.1% vs. 10.5%
(risk difference, 10.6 percentage points; 95% CI, 2.8 to 18.4)
QuizartinibのP3試験（r/r FLT3-ITD AML）
(NCT02039726、Lancet Oncol. 2019;20:984-997.)
計367症例（Primary end point：OS）
Gilteritinib (n = 245) vs. Salvage chemotherapy (n = 122)
Median OS: 6.2 (95% CI 5.3-7.2) vs. 4.7 (95% CI 4.0-5.5)
(OS, hazard ratio 0.76 [95% CI 0.58-0.98; p=0.02]).
Median Age: 55.0 vs. 57.5